SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of April 2005

Commission File Number 000-51122

pSivida Limited

(Translation of registrant's name into English)

Level 12 BGC Centre
28 The Esplanade
Perth WA 6000
(Address of principal executive offices)

(Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F).

Form 20-F ☒ Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- ___.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant, pSivida Limited, has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

pSivida Limited

Date: May 3, 2005

By: /s/ Aaron Finlay

Aaron Finlay
Chief Financial Officer and Company Secretary

EXHIBIT INDEX

EXHIBIT 99.1: pSivida ASX Release ESTRO 030505

ASX/MEDIA RELEASE

3rd May 2005

BrachySil™ to be Presented at Annual ESTRO Conference

European Society for Therapeutic & Radiation Oncology

Global nanotechnology company pSivida Limited **(ASX:PSD, NASDAQ:PSDV, Xetra:PSI)** is pleased to announce that current data from its lead cancer product BrachySil™ will be presented at this year's European Society for Therapeutic and Radiation Oncology Conference in Budapest on 5th May 2005. The conference is an opportunity to share and validate the Company's promising findings with an international scientific, clinical and industrial audience.

Data on all 8 planned patients has demonstrated marked tumor regression as determined by CT scanning, up to 100% in some smaller tumors. This study represents the first step in the regulatory programme leading to product approval and was specifically focussed on the safety and tolerability of this proprietary treatment for solid tumors. Importantly the study has found that all patients tolerated study procedures and the investigational treatment well, with no significant product-related findings and with all patients discharged from the clinic the day following treatment.

BrachySil™ is a micron sized particle in which the isotope 32 phosphorus is immobilised. pSivida believes that this product is advantageous in that it demonstrates a high degree of isotope targeting and retention, thus maximising the therapeutic load on the tumor whilst reducing the risk of radioactivity affecting healthy hepatic tissue or entering the systemic circulation; a finding borne out by the data from this critical study.

pSivida's commercialisation strategy as an R&D-focussed business is to seek a sales and marketing partner for the product.

pSivida also announced on the 8th April 2005 that the Company would be commencing a Phase IIa human clinical trial using BrachySil™ later this year for pancreatic tumors as a second market for BrachySil™, in addition to liver tumors. It is expected that the BrachySil™ product will also be applicable to a range of other solid tumor cancer markets which the Company intends to progressively address.

-ENDS-

Released by:

In Australia:
Josh Mann, CFA
Investor Relations
pSivida Limited
Tel: + 61 8 9226 5099
joshuamann@psivida.com

In US:
Beverly Jedynak
President
Martin E. Janis & Company, Inc.
Tel: 312-943-1100 ext. 12
bjedynak@janispr.com

NOTES TO EDITORS:

pSivida Limited

pSivida is a global nanotechnology company committed to the biomedical sector and the development of products in healthcare. The company's focus is the development and commercialisation of a modified form of silicon (porosified or nano-structured silicon) known as BioSilicon™. As a new and exciting biocompatible material, BioSilicon™ offers multiple potential applications across the high growth healthcare sector, including controlled release drug delivery, targeted cancer therapies (including brachytherapy and localized chemotherapy), tissue engineering and orthopedics. Potential diagnostics applications are being developed through its subsidiary AION Diagnostics Limited.

pSivida owns the intellectual property rights to BioSilicon™ for use in or on humans and animals. The IP portfolio consists of 24 patent families, 28 granted patents and over 80 patent applications. The core patent, which recognises BioSilicon™ as a biomaterial was granted in the UK in 2000 and in the US in 2001.

pSivida is listed on NASDAQ (**PSDV**), the Australian Stock Exchange (**PSD**) and in Germany on the Frankfurt Stock Exchange on the XETRA system (**German Symbol: PSI. Securities Code (WKN) 358705**). pSivida's shares also trade in the United Kingdom on the OFEX International Market Service (IMS) under the ticker symbol **PSD**.

The Company's strategic partner and largest shareholder is the QinetiQ group, the largest science and technology company in Europe. QinetiQ is the former UK government Defence Evaluation Research Agency and was instrumental in discovering BioSilicon™. pSivida enjoys a strong relationship with QinetiQ having access to its cutting edge research and development facilities. For more information on QinetiQ visit www.qinetiq.com.

For more information visit www.psivida.com